| Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis. | 2023 | Annals of the Rheumatic Diseases |
| Efficacy and safety of secukinumab for the treatment of psoriasis: A meta-analysis of pivotal phase III trials | 2023 | Dermatology |
| Clinical and Economic Benefit of Advanced Therapies for the Treatment of Active Ankylosing Spondylitis | 2023 | Rheumatology and therapy |
| Optimization of secukinumab dose regimens in patients with moderate-to-severe plaque psoriasis via exposure-response modeling | 2023 | Expert review of clinical pharmacology |
| Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year. | 2022 | Journal of Dermatological Treatment |
| Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis. | 2022 | Cochrane Database of Systematic Reviews |
| Assessment report: Cosentyx. | 2022 | EMA |
| Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: a systematic literature review and a network meta-analysis. | 2022 | Dermatology and Therapy |
| Bullous pemphigoid induced by biologic drugs in psoriasis: a systematic review. | 2022 | Journal of Dermatological Treatment |
| Biologics for pediatric moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. | 2022 | Journal of the German Society of Dermatology |
| Biologic disease-modifying antirheumatic drugs for preventing radiographic progression in psoriatic arthritis: a systematic review and network meta-analysis. | 2022 | Pharmaceutics |
| Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular. dermatological, enthesitis and dactylitis outcomes. | 2022 | Rheumatic & Muscoskeletal Diseases |
| Biologics for pediatric psoriasis: A systematic review and meta-analysis | 2022 | Pediatric dermatology |
| Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis | 2022 | Dermatology and therapy |
| Towards Personalized Medicine in Psoriasis: Current Progress | 2022 | Psoriasis |
| Comparative Efficacy and Safety of Janus Kinase Inhibitors and Secukinumab in Patients with Active Ankylosing Spondylitis: A Systematic Review and Meta-Analysis | 2022 | Pharmacology |
| Understanding efficacy-safety balance of biologics in moderate-to-severe pediatric psoriasis | 2022 | Frontiers in medicine |
| Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis | 2022 | Advances in therapy |
| Comparative Efficacy of Biologic Disease-Modifying Anti-Rheumatic Drugs for Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Bucher Indirect Comparisons | 2022 | Inflammopharmacology |
| Evidence for the Use of Secukinumab in Patients with Radiographic and Non-radiographic Axial Spondyloarthritis in the Last 5 Years | 2022 | Rheumatology and therapy |
| Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis | 2022 | Chinese medical journal |
| Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies | 2022 | Seminars in arthritis and rheumatism |
| Impact of biologics on health-related quality of life in patients with Ankylosing spondylitis: A systematic review and meta-analysis of randomized controlled trials | 2022 | Seminars in arthritis and rheumatism |
| Secukinumab for treating non-radiographic axial spondyloarthritis. | 2021 | NICE |
| Dose adjustment of biologic treatments for moderate-to-severe plaque psoriasis in the real world: a systematic review. | 2021 | Dermatology and Therapy |
| Efficacy and safety of interleukin-17A inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials. | 2021 | Clinical Rheumatology |
| Efficacy and safety of anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a meta-analysis. | 2021 | Monoclonal Antibodies in Immunodiagnosis and Immunotherapy |
| Differences in biologics for treating ankylosing spondylitis: the contribution of network meta-analysis. | 2021 | European Review for Medical and Pharmacological Sciences |
| Efficacy and safety of interleukin-17 inhibitors in the treatment of chronic rheumatic diseases: a combined and updated meta-analysis. | 2021 | Journal of Clinical Pharmacy and Therapeutics |
| Comparative efficacy and relative ranking of biologics and oral therapies for moderate-to-severe plaque psoriasis: a network meta-analysis. | 2021 | Dermatologic Therapy |
| Relative efficacy and safety of secukinumab and guselkumab for the treatment of active psoriatic arthritis: a network meta-analysis. | 2021 | International Journal of Clinical Pharmacology and Therapeutics |
| Comparative efficacy and safety of secukinumab, ixekizumab, and tofacitinib in patients with active psoriatic arthritis showing insufficient response to tumor necrosis factor inhibitors. | 2021 | International Journal of Clinical Pharmacology and Therapeutics |
| A systematic review with network meta-analysis of the available biologic therapies for psoriatic disease domains. | 2021 | Frontiers in Medicine |
| Secukinumab for treating moderate to severe plaque psoriasis in children and young people. | 2021 | NICE |
| Short-term efficacy of biologic therapies in moderate-to-severe plaque psoriasis: a systematic literature review and an enhanced multinomial network meta-analysis. | 2021 | Dermatology and Therapy |
| Impact of biological agents on imaging and biomarkers of cardiovascular disease in patients with psoriasis: a systematic review and meta-analysis of randomized placebo-controlled trials. | 2021 | Journal of Investigative Dermatology |
| Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies | 2021 | Rheumatology and therapy |
| Comparative efficacy and safety of secukinumab and ixekizumab in patients with active ankylosing spondylitis | 2021 | Zeitschrift fur Rheumatologie |
| A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis | 2021 | Rheumatology and therapy |
| Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies | 2021 | The Journal of rheumatology |
| Comparative efficacy and safety of secukinumab 75 mg, 150 mg, and 300 mg in patients with active ankylosing spondylitis | 2021 | International journal of clinical pharmacology and therapeutics |
| Short-term efficacy and safety of secukinumab for ankylosing spondylitis: a systematic review and meta-analysis of RCTs. | 2020 | Mediators of Inflammation |
| Drug survival of biologics in treating ankylosing spondylitis: a systematic review and meta-analysis of real-world evidence. | 2020 | BioDrugs |
| Effectiveness and safety of systemic therapy for psoriasis in older adults: a systematic review. | 2020 | JAMA Dermatology |
| The effects of selected biologics and a small molecule on health-related quality of life in adult plaque psoriasis patients: a systematic review and meta-analysis. | 2020 | PLoS One |
| Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis | 2020 | The British journal of dermatology |
| Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis | 2020 | Annals of the rheumatic diseases |
| Treatment of Dactylitis and Enthesitis in Psoriatic Arthritis with Biologic Agents: A Systematic Review and Metaanalysis | 2020 | The Journal of rheumatology |
| Fourteen small molecule and biological agents for psoriatic arthritis: A network meta-analysis of randomized controlled trials | 2020 | Medicine |
| Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis | 2020 | Arthritis research & therapy |
| Biological DMARD efficacy in psoriatic arthritis: a systematic literature review and meta-analysis on articular, enthesitis, dactylitis, skin and functional outcomes | 2020 | Clinical and experimental rheumatology |
| Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses | 2020 | Dermatology and therapy |
| Short-term efficacy and safety of il-17, il-12/23, and il-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials. | 2019 | Journal of Immunology Research |
| Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data | 2019 | Arthritis research & therapy |
| Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies | 2019 | Arthritis research & therapy |
| Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response | 2019 | PloS one |
| A Cost-per-Number Needed to Treat Analysis Assessing the Efficiency of Biologic Drugs in Moderate to Severe Plaque Psoriasis | 2019 | Actas dermo-sifiliograficas |
| A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis | 2018 | The Journal of dermatological treatment |
| A Systematic Review and Meta-analysis of Efficacy and Safety of Novel Interleukin Inhibitors in the Management of Psoriatic Arthritis | 2018 | Journal of clinical rheumatology |
| Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis | 2018 | Journal of comparative effectiveness research |
| Relative efficacy and safety of apremilast, secukinumab, and ustekinumab for the treatment of psoriatic arthritis | 2018 | Zeitschrift fur Rheumatologie |
| Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis | 2018 | Rheumatology international |
| Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison | 2018 | European journal of rheumatology |
| Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies | 2018 | Drugs & aging |
| Risk of serious infections in biological treatment of patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis | 2018 | Clinical rheumatology |
| Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies | 2018 | Dermatology and therapy |
| Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis | 2018 | Current medical research and opinion |
| Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan | 2018 | The Journal of dermatological treatment |
